- Home
- / Arcellx
Arcellx
Stock Price
$87.3
2024-10-29
Market Capitalization
$4.7 B
2024-10-28
Revenue
$22.3 M
FY, 2025
Arcellx Summary
Company Summary
- Overview
- Arcellx is a clinical-stage biotechnology company developing adaptive immune cell therapies. It develops Antigen Receptor Complex T cell (ARC-T) therapies focusing on the treatment of cancer and other incurable diseases.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Gaithersburg, MD, US | view all locations
- Website
- https://www.arcellx.com/
- Cybersecurity rating
Table of Contents
Key People
Christopher Heery, Chief Medical Officer
David Tice, Chief Scientific Officer
Narinder Singh, Chief Technical Officer
LocationsView all
1 location detected
Gaithersburg, MD HQ
United States
25 West Watkins Mill Road, Suite A
Arcellx Financials
Summary Financials
- Revenue (FY, 2025)
- $22.3M
- Net income (FY, 2025)
- ($228.9M)
- Cash (FY, 2025)
- $80.3M
- EBIT (FY, 2025)
- ($253.1M)
- Enterprise value
- $4.7B